

20 July 2023

ASX Announcement

Firebrick Update on AAT Process

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) advises the market that the scheduled conciliation meeting with the TGA, which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023.

The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine® Nasal Spray (“Nasodine”). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded with the mission to commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also has a third patent family covering the Nasodine formulation, which has been granted in Australia. Firebrick is currently completing a second Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results will also be important for securing regulatory approvals and partnerships in major markets outside Australia.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com